{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:56:16Z","timestamp":1792454176819,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2020CXJQ02"],"award-info":[{"award-number":["2020CXJQ02"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141101"],"award-info":[{"award-number":["82141101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2505005"],"award-info":[{"award-number":["2022YFC2505005"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["82503804"],"award-info":[{"award-number":["82503804"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M772399"],"award-info":[{"award-number":["2025M772399"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtho.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:56:13Z","timestamp":1760072173000},"page":"103494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Xiaoshen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaokai","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.10.001_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.10.001_bib2","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (Pioneer)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.10.001_bib4","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.10.001_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2025.10.001_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0936","article-title":"Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state","volume":"11","author":"Echeverria","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2025.10.001_bib7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2025.10.001_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","article-title":"Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells","volume":"23","author":"Roesch","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2025.10.001_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jtho.2025.10.001_bib10","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1038\/onc.2014.372","article-title":"A stress-induced early innate response causes multidrug tolerance in melanoma","volume":"34","author":"Ravindran Menon","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2025.10.001_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2025.10.001_bib12","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.7150\/thno.42523","article-title":"Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer","volume":"10","author":"Ravindran Menon","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jtho.2025.10.001_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav7416","article-title":"Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms","volume":"6","author":"Aldonza","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.jtho.2025.10.001_bib94","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1038\/s41388-019-0887-2","article-title":"Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer","volume":"38","author":"Raoof","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2025.10.001_bib27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2020.01.015","article-title":"AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug-resistant cancer cells","volume":"15","author":"Lotsberg","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.10.001_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.10.001_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1593\/neo.91384","article-title":"GAS6\/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche","volume":"12","author":"Shiozawa","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.jtho.2025.10.001_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2025.10.001_bib17","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.10.001_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jtho.2025.10.001_bib19","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cancers12071987","article-title":"Tumor-associated macrophage status in cancer treatment","volume":"12","author":"Malfitano","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.10.001_bib20","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","article-title":"Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.10.001_bib21","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","article-title":"AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.10.001_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160152","article-title":"Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse","volume":"132","author":"Nie","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtho.2025.10.001_bib23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/cns.13800","article-title":"Curzerene suppresses progression of human glioblastoma through inhibition of glutathione S-transferase A4","volume":"28","author":"Cheng","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.jtho.2025.10.001_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-018-0871-7","article-title":"MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma","volume":"37","author":"Ferrer","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13046-019-1240-x","article-title":"Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC","volume":"38","author":"La Monica","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib26","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1349-7006.1997.tb00350.x","article-title":"Anti-tumor efficacy of paclitaxel against human lung cancer xenografts","volume":"88","author":"Yamori","year":"1997","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113771","article-title":"Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma","volume":"43","author":"Liang","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2025.10.001_bib29","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s41418-023-01222-0","article-title":"C-IGF1R encoded by cIGF1R acts as a molecular switch to restrict mitophagy of drug-tolerant persister tumour cells in non-small cell lung cancer","volume":"30","author":"Wang","year":"2023","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtho.2025.10.001_bib30","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.10.001_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2011-0320-OA","article-title":"Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray","volume":"136","author":"Turner","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.10.001_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2008.01.005","article-title":"Doubting the TCR coreceptor function of CD8alphaalpha","volume":"28","author":"Cheroutre","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2025.10.001_bib33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.21678","article-title":"TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous \u03b1\u03b2 T-cell lymphomas with peripheral blood involvement","volume":"187","author":"Martin-Moro","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtho.2025.10.001_bib34","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41590-019-0479-x","article-title":"Flip the coin: il-7 and IL-7R in health and disease","volume":"20","author":"Barata","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtho.2025.10.001_bib35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/onc.2012.269","article-title":"ENTPD1\/CD39 is a promising therapeutic target in oncology","volume":"32","author":"Bastid","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2025.10.001_bib36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtho.2025.10.001_bib37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jcb.240560417","article-title":"Regulation and specificity of MNDA expression in monocytes, macrophages, and leukemia\/B lymphoma cell lines","volume":"56","author":"Briggs","year":"1994","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jtho.2025.10.001_bib38","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCRESAHA.124.324106","article-title":"Lysozyme 1 inflamed CCR2+ macrophages promote obesity-induced cardiac dysfunction","volume":"135","author":"Zhang","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib39","first-page":"27","article-title":"Single-cell transcriptome profiling of sepsis identifies HLA-DRlowS100Ahigh monocytes with immunosuppressive function","volume":"10","author":"Yao","year":"2023","journal-title":"Mil Med Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib40","doi-asserted-by":"crossref","first-page":"25712","DOI":"10.1073\/pnas.2002476117","article-title":"Genetic landscape and autoimmunity of monocytes in developing Vogt-Koyanagi-Harada disease","volume":"117","author":"Hu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.10.001_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jtho.2025.10.001_bib42","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtho.2025.10.001_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.2021014840","article-title":"CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies","volume":"140","author":"Bueno","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2025.10.001_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/srep38655","article-title":"Structural basis for human PECAM-1-Mediated trans-homophilic cell adhesion","volume":"6","author":"Hu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2025.10.001_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor","volume":"67","author":"Sadler","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jtho.2025.10.001_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/ATVBAHA.107.158014","article-title":"VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation","volume":"28","author":"Vestweber","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtho.2025.10.001_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12987-023-00424-5","article-title":"The CLDN5 gene at the blood-brain barrier in health and disease","volume":"20","author":"Hashimoto","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.jtho.2025.10.001_bib48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fmed.2019.00010","article-title":"Endoglin as an adhesion molecule in mature and progenitor endothelial cells: a function beyond TGF-\u03b2","volume":"6","author":"Rossi","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtho.2025.10.001_bib49","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41467-020-15647-5","article-title":"Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis","volume":"11","author":"Tsukui","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.10.001_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54385-w","article-title":"Vasculogenic skin reprogramming requires TET-mediated gene demethylation in fibroblasts for rescuing impaired perfusion in diabetes","volume":"15","author":"Mohanty","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.10.001_bib51","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1038\/s41388-018-0209-0","article-title":"Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing","volume":"37","author":"Miskolczi","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2025.10.001_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.798331","article-title":"Single-cell transcriptome integration analysis reveals the correlation between mesenchymal stromal cells and fibroblasts","volume":"13","author":"Fan","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.jtho.2025.10.001_bib53","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0002-9440(10)63488-8","article-title":"Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes","volume":"163","author":"Koumas","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2025.10.001_bib54","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2025.10.001_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jtho.2025.10.001_bib56","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.10.001_bib57","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.10.001_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115233","article-title":"Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS\/MS","volume":"225","author":"de Leeuw","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jtho.2025.10.001_bib59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/cancers15041092","article-title":"Association between plasminogen activator inhibitor-1 and osimertinib tolerance in EGFR-mutated lung cancer via epithelial-mesenchymal transition","volume":"15","author":"Tokumo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.10.001_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41698-022-00337-w","article-title":"The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells","volume":"6","author":"Criscione","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtho.2025.10.001_bib61","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/0008-5472.CAN-23-0438","article-title":"ASCL1 drives tolerance to osimertinib in EGFR mutant lung cancer in permissive cellular contexts","volume":"84","author":"Hu","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib62","first-page":"23","article-title":"Cytotoxic and antitumor effects of curzerene from Curcuma longa","volume":"83","author":"Wang","year":"2017","journal-title":"Planta Med"},{"key":"10.1016\/j.jtho.2025.10.001_bib63","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/antiox10050701","article-title":"Glutathione S-transferases in cancer","volume":"10","author":"Singh","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jtho.2025.10.001_bib64","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1038\/s41467-023-41229-2","article-title":"ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia","volume":"14","author":"Ebner","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.10.001_bib65","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1083\/jcb.87.2.386","article-title":"Calmodulin confers calcium sensitivity on ciliary dynein ATPase","volume":"87","author":"Blum","year":"1980","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jtho.2025.10.001_bib66","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1091\/mbc.e11-12-1056","article-title":"Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis","volume":"23","author":"Plotnikova","year":"2012","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jtho.2025.10.001_bib67","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1159\/000515225","article-title":"Calmodulin regulates ciliary beats in the human nasal mucosa through adenylate\/guanylate cyclases and protein kinases A\/G","volume":"182","author":"Nguyen","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jtho.2025.10.001_bib68","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1083\/jcb.200912009","article-title":"Pcdp1 is a central apparatus protein that binds Ca(2+)-calmodulin and regulates ciliary motility","volume":"189","author":"DiPetrillo","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jtho.2025.10.001_bib69","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/sj.cdd.4401042","article-title":"Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis","volume":"9","author":"Schwab","year":"2002","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtho.2025.10.001_bib70","article-title":"Manipulating calcium homeostasis with nanoplatforms for enhanced cancer therapy","volume":"4","author":"Feng","year":"2023","journal-title":"Exploration (Beijing)"},{"key":"10.1016\/j.jtho.2025.10.001_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2022.102673","article-title":"Calcium signaling: a therapeutic target to overcome resistance to therapies in cancer","volume":"108","author":"Romito","year":"2022","journal-title":"Cell Calcium"},{"key":"10.1016\/j.jtho.2025.10.001_bib72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/cancers9050048","article-title":"Targeting intracellular calcium signaling ([Ca2+]i) to overcome acquired multidrug resistance of cancer cells: a mini-overview","volume":"9","author":"B\u00fcsselberg","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.10.001_bib73","series-title":"Encyclopedia of Signaling Molecules","author":"Kirberger","year":"2017"},{"key":"10.1016\/j.jtho.2025.10.001_bib74","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00018-019-03062-z","article-title":"Proteins with calmodulin-like domains: structures and functional roles","volume":"76","author":"Villalobo","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jtho.2025.10.001_bib75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"AXL in cancer: a modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib76","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10637-023-01341-y","article-title":"Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study","volume":"41","author":"Yang","year":"2023","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jtho.2025.10.001_bib77","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.1002\/cam4.5508","article-title":"Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer","volume":"12","author":"Goto","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2025.10.001_bib78","doi-asserted-by":"crossref","first-page":"9110","DOI":"10.1200\/JCO.2021.39.15_suppl.9110","article-title":"Ph I\/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: end of trial update","volume":"39","author":"Byers","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.001_bib79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0076-6879(05)01002-5","article-title":"Human alpha class glutathione S-transferases: genetic polymorphism, expression, and susceptibility to disease","volume":"401","author":"Coles","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.jtho.2025.10.001_bib80","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0090-9556(25)07498-7","article-title":"Busulfan conjugation by glutathione S-transferases alpha, mu, and pi","volume":"24","author":"Czerwinski","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jtho.2025.10.001_bib81","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2125.2008.03321.x","article-title":"Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa","volume":"67","author":"Ekhart","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtho.2025.10.001_bib82","first-page":"1701","article-title":"The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa","volume":"55","author":"Dirven","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.001_bib83","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-1-4615-4811-9_22","article-title":"Evidence for the involvement of the glutathione pathway in drug resistance in AML","volume":"457","author":"Sargent","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jtho.2025.10.001_bib84","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clim.2015.07.010","article-title":"The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients","volume":"160","author":"Wang","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jtho.2025.10.001_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056337","article-title":"The interaction of the chemotherapeutic drug chlorambucil with human glutathione transferase A1-1: kinetic and structural analysis","volume":"8","author":"Karpusas","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2025.10.001_bib86","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ijc.10896","article-title":"Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment","volume":"103","author":"Sweeney","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2025.10.001_bib87","article-title":"Targeting GSTP1 as therapeutic strategy against lung adenocarcinoma stemness and resistance to tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jtho.2025.10.001_bib88","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.celrep.2018.05.016","article-title":"Primary cilia mediate diverse kinase inhibitor resistance mechanisms in cancer","volume":"23","author":"Jenks","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2025.10.001_bib89","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1172\/JCI97354","article-title":"Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response","volume":"128","author":"Ubil","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtho.2025.10.001_bib90","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41401-022-01047-6","article-title":"AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage","volume":"44","author":"Pei","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jtho.2025.10.001_bib91","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/glia.23214","article-title":"Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposure","volume":"65","author":"Ray","year":"2017","journal-title":"Glia"},{"key":"10.1016\/j.jtho.2025.10.001_bib92","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.10.001_bib93","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib resistance: molecular mechanisms and emerging treatment options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425028461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425028461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:38Z","timestamp":1778819318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425028461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1556086425028461"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.10.001","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103494"}}